CBLL Stock Analysis: CeriBell | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 751m USD | 12M Return: 16.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.42M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CeriBell, Inc. is a U.S.-based medical technology company headquartered in Sunnyvale, California, founded in 2014 (originally as Brain Stethoscope, Inc., renamed in August 2015). The company listed on NASDAQ in October 2024 under the ticker CBLL and operates within the Health Care Equipment sub-industry.
CeriBells core product is the Ceribell System, a point-of-care EEG (electroencephalography) platform developed for acute care settings such as emergency departments and intensive care units, where rapid brain monitoring is often critical. The platform combines disposable headbands and headcaps with a pocket-sized, rechargeable recorder that captures and wirelessly transmits EEG signals, addressing the traditional challenge of limited access to neurology specialists in time-sensitive environments.
The company also offers Clarity, an AI-powered seizure detection algorithm, along with a cloud-based EEG portal that allows clinicians real-time remote access to patient brain data. Together, these components form an integrated hardware-plus-software business model that combines recurring revenue from disposable headbands with software-enabled diagnostic services.
- Ceribell System adoption accelerates across hospital acute care settings
- Clarity AI seizure detection algorithm drives recurring disposable revenue
- Competition intensifies from traditional EEG and emerging neurodiagnostics platforms
| Net Income: -60.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA -9.79 > 1.0 |
| NWC/Revenue: 158.3% < 20% (prev 272.4%; Δ -114.1% < -1%) |
| CFO/TA -0.27 > 3% & CFO -48.7m > Net Income -60.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.7m) vs 12m ago 4.97% < -2% |
| Gross Margin: 87.72% > 18% (prev 87.24%; Δ 0.48% > 0.5%) |
| Asset Turnover: 48.56% > 50% (prev 33.30%; Δ 15.26% > 0%) |
| Interest Coverage Ratio: -31.58 > 6 (EBIT TTM -58.5m / Interest Expense TTM 1.85m) |
| A: 0.85 (Total Current Assets 166.7m - Total Current Liabilities 16.2m) / Total Assets 178.1m |
| B: -1.35 (Retained Earnings -240.1m / Total Assets 178.1m) |
| C: -0.30 (EBIT TTM -58.5m / Avg Total Assets 195.8m) |
| D: 3.78 (Book Value of Equity 140.8m / Total Liabilities 37.3m) |
| Altman-Z'' = 3.11 = A |
| DSRI: 1.04 (Receivables 15.7m/11.3m, Revenue 95.1m/71.1m) |
| GMI: 0.99 (GM 87.24% / 87.72%) |
| AQI: 2.21 (AQ_t 0.04 / AQ_t-1 0.02) |
| SGI: 1.34 (Revenue 95.1m / 71.1m) |
| TATA: -0.07 (NI -60.4m - CFO -48.7m) / TA 178.1m) |
| Beneish M = -2.05 (Cap -4..+1) = BB |
As of July 11, 2026, the stock is trading at USD 19.56 with a total of 190,874 shares traded. Over the past week, the price has changed by +0.05%, over one month by +6.42%, over three months by +7.77% and over the past year by +16.71%.
Current recommended Stop Loss: 18.60 (which is 4.9% or 1.2 ATR below the current price).
CeriBell has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy CBLL.
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.9 | 37.3% |
P/S = 7.8986
P/B = 5.2666
Revenue TTM = 95.1m USD
EBIT TTM = -58.5m USD
EBITDA TTM = -57.3m USD
Long Term Debt = 19.9m USD (from longTermDebt, last quarter)
Short Term Debt = 1.14m USD (from shortTermDebt, last quarter)
Debt = 24.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.20m
Net Debt = -116.9m USD (calculated: Debt 24.3m - CCE 141.2m)
Enterprise Value = 634.0m USD (750.9m + Debt 24.3m - CCE 141.2m)
Interest Coverage Ratio = -31.58 (Ebit TTM -58.5m / Interest Expense TTM 1.85m)
EV/FCF = -12.82x (Enterprise Value 634.0m / FCF TTM -49.4m)
FCF Yield = -7.80% (FCF TTM -49.4m / Enterprise Value 634.0m)
FCF Margin = -52.01% (FCF TTM -49.4m / Revenue TTM 95.1m)
Net Margin = -63.51% (Net Income TTM -60.4m / Revenue TTM 95.1m)
Gross Margin = 87.72% ((Revenue TTM 95.1m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = 87.27% (prev 87.33%)
Tobins Q-Ratio = 3.56 (Enterprise Value 634.0m / Total Assets 178.1m)
Interest Expense / Debt = 7.62% (Interest Expense 1.85m / Debt 24.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -46.2m (EBIT -58.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.30 (Total Current Assets 166.7m / Total Current Liabilities 16.2m)
Debt / Equity = 0.17 (Debt 24.3m / totalStockholderEquity, last quarter 140.8m)
Debt / EBITDA = 2.04 (negative EBITDA) (Net Debt -116.9m / EBITDA -57.3m)
Debt / FCF = 2.36 (negative FCF - burning cash) (Net Debt -116.9m / FCF TTM -49.4m)
Total Stockholder Equity = 158.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.84% (Net Income -60.4m / Total Assets 178.1m)
RoE = -38.19% (Net Income TTM -60.4m / Total Stockholder Equity 158.1m)
RoCE = -32.87% (EBIT -58.5m / Capital Employed (Equity 158.1m + L.T.Debt 19.9m))
RoIC = -29.21% (negative operating profit) (NOPAT -46.2m / Invested Capital 158.3m)
WACC = 9.19% (E(750.9m)/V(775.2m) * Re(9.29%) + D(24.3m)/V(775.2m) * Rd(7.62%) * (1-Tc(0.21)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.40 | Cagr: 23.74%
[DCF] Fair Price = unknown (Cash Flow -49.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 99.86 | Revenue CAGR: 40.33% | SUE: 0.63 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.46 | Chg30d=-17.57% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-5.56% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.68 | Chg30d=-15.51% | Revisions=-50% | GrowthEPS=-15.2% | GrowthRev=+28.0%
EPS next Year (2027-12-31): EPS=-1.10 | Chg30d=-9.22% | Revisions=-29% | GrowthEPS=+34.7% | GrowthRev=+28.0%
[Analyst] Revisions Ratio: -56% (up=2, down=11)